Abstract
Anemia in dialysis patients is common and includes deficiency of erythropoietin (Epo), treated by hormone replacement therapy and oral and intravenous iron that, in its free form, mainly contributes to the increased production of radical species and to the chronic oxidative stress observed in these patients. In an attempt to reduce this pro-oxidative environment caused by treatments (dial…